Adage Capital Partners GP L.L.C. Sells 285,581 Shares of Sanofi (NASDAQ:SNY)

Adage Capital Partners GP L.L.C. lessened its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 37.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 480,416 shares of the company's stock after selling 285,581 shares during the period. Adage Capital Partners GP L.L.C.'s holdings in Sanofi were worth $23,170,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Invesco Ltd. grew its stake in shares of Sanofi by 3.5% during the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after acquiring an additional 408,752 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the period. Boston Partners boosted its position in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the period. Franklin Resources Inc. boosted its holdings in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after buying an additional 369,530 shares during the period. Finally, Magnetar Financial LLC raised its holdings in Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Trading Down 2.3 %

Shares of SNY opened at $52.32 on Friday. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company's fifty day moving average is $54.53 and its 200 day moving average is $52.09. The stock has a market capitalization of $132.17 billion, a PE ratio of 21.01, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is 57.14%.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent analyst reports. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Finally, BNP Paribas initiated coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of "Moderate Buy" and a consensus target price of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.